{"transactions":[{"id":2444379,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":131620,"kind":"person","name":"Meyenburg Jason Patrick","position":1,"cik":"0001709008","reported_name":"Meyenburg Jason Patrick","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-05T21:08:07.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":123600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These Restricted Stock Units shall vest in accordance with certain performance based metrics."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These Restricted Stock Units shall vest in accordance with certain performance based metrics."}],"balance_after":123600,"derivative":{"underlying":"Common Stock","underlying_shares":123600},"source":{"system":"sec-edgar","filing":"0001209191-22-001634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000120919122001634/doc4.xml","form_type":"4"}},{"id":2708403,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":131620,"kind":"person","name":"Meyenburg Jason Patrick","position":1,"cik":"0001709008","reported_name":"Meyenburg Jason Patrick","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-05-18T20:45:25.000Z","date":"2021-05-14","kind":"purchase","acquired":true,"shares":13000,"price":9.4561,"value":122929.3,"ownership":{"direct":true},"balance_after":13000,"source":{"system":"sec-edgar","filing":"0000899243-21-019762","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000089924321019762/doc4.xml","form_type":"4"}},{"id":2754531,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":131620,"kind":"person","name":"Meyenburg Jason Patrick","position":1,"cik":"0001709008","reported_name":"Meyenburg Jason Patrick","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-07T20:03:56.000Z","date":"2021-02-05","kind":"grant","acquired":true,"shares":1124832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company."}],"balance_after":1124832,"derivative":{"exercise_price":12.66,"expiration_date":"2031-02-04","underlying":"Common Stock","underlying_shares":1124832},"source":{"system":"sec-edgar","filing":"0001213900-21-020623","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000121390021020623/ownership.xml","form_type":"4"}},{"id":4062232,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":131620,"kind":"person","name":"Meyenburg Jason Patrick","position":1,"cik":"0001709008","reported_name":"Meyenburg Jason Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-13T16:41:36.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":150000,"price":7.35,"value":1102500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the \"Option Spread\"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":10.65,"expiration_date":"2027-04-03","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001171843-18-001100","document":"f4_meyenburg021318.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318001100/f4_meyenburg021318.xml","form_type":"4"}},{"id":4062231,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":131620,"kind":"person","name":"Meyenburg Jason Patrick","position":1,"cik":"0001709008","reported_name":"Meyenburg Jason Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock, Class A","published_at":"2018-02-13T16:41:36.000Z","date":"2018-02-13","kind":"disposition_to_issuer","acquired":false,"shares":30228,"price":18,"value":544104.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This common stock was purchased for $18.00 per share share in cash, subject to any required withholding of taxes and without interest, upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to that certain Agreement and Plan of Merger by and among Mallinckrodt plc, Sun Acquisition Co. and Sucampo Pharmaceuticals, Inc. dated December 23, 2017 (the \"Merger Agreement\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001171843-18-001100","document":"f4_meyenburg021318.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184318001100/f4_meyenburg021318.xml","form_type":"4"}},{"id":4213392,"issuer":{"id":169352,"kind":"organization","name":"Sucampo Pharmaceuticals, Inc.","symbol":"SCMP"},"owners":[{"id":131620,"kind":"person","name":"Meyenburg Jason Patrick","position":1,"cik":"0001709008","reported_name":"Meyenburg Jason Patrick","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock, Class A","published_at":"2017-09-08T16:40:37.000Z","date":"2017-09-06","kind":"purchase","acquired":true,"shares":4000,"price":12.125,"value":48500.0,"ownership":{"direct":true},"balance_after":30228,"source":{"system":"sec-edgar","filing":"0001171843-17-005464","document":"formfour.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1365216/000117184317005464/formfour.xml","form_type":"4"}}]}